Skip to content
DataLookout
Menu

SHARP SCLCNCT07920549

A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression-Free Survival in Limited-Stage Small Cell Lung Cancer

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Nov 8, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.

All 1 version: 1 with changes below. See every version on ClinicalTrials.gov ↗

  1. Study First Submitted

Endpoints

Primary

Progression-free survival
Timeframe: From randomization to disease progression or death, assessed for up to 60 months.

Secondary (6)

Changes in Quality of Life Measured by the Functional Assessment of Cancer Therapy: Lung (FACT-L), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaires
Acute and Chronic Physician-Reported Toxicity Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Overall Survival
Freedom From Intrathoracic Progression
Freedom From Intracranial Progression
Show 1 moreShow less
Cost-Effectiveness Analysis

Arms and interventions

Standard Thoracic RadiotherapyActive comparator
Hypofractionated Accelerated Thoracic RadiotherapyExperimental

Radiation: Radiation Therapy, Hypofractionated Radiation Therapy

Drugs: Chemotherapy

Sites

1 site in 1 country

  • London Health Sciences Centre, Verspeeten Family Cancer CentreLondon, Ontario, Canada